Head-To-Head Survey: PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS)

Alpha Tau Medical (NASDAQ:DRTS) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Alpha Tau Medical and PAVmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-138.12%	-81.68%
PAVmed	-21,914.12%	-146.19%	-18.39%

Institutional & Insider Ownership

2.6% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by insiders. Comparatively, 13.4% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Alpha Tau Medical and PAVmed”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63 million	($1.04)	-13.70
PAVmed	$85,000.00	60.93	$400,000.00	($37.40)	-0.14

PAVmed has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Alpha Tau Medical and PAVmed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	1	2	5	0	2.50
PAVmed	1	1	1	0	2.00

Alpha Tau Medical currently has a consensus target price of $12.80, indicating a potential downside of 10.18%. PAVmed has a consensus target price of $56.00, indicating a potential upside of 976.92%. Given PAVmed’s higher probable upside, analysts plainly believe PAVmed is more favorable than Alpha Tau Medical.

Volatility & Risk

Alpha Tau Medical has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Summary

Alpha Tau Medical beats PAVmed on 7 of the 13 factors compared between the two stocks.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.